Bioimpedance analyzers are becoming part of larger health technology systems, including smart wearable medical devices and telemedicine equipment, enabling smooth data sharing and compatibility. The growing focus of manufacturers towards integrating wearable devices with bioimpedance analyzers has enabled continuous measurement of body composition and real time data sharing.
According to a study in The American Journal of Nutritional Medicine (November 2022), smartwatches with integrated bioimpedance analyzers will provide stable, reliable, and accurate body composition measurements, albeit slightly less precise than lab measures.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Industry size for bioimpedance analyzer was recorded USD 515.3 million in 2023 and will grow at a 10.4% CAGR between 2024 and 2032 owing to heightened emphasis on health and wellness across demographics coupled with the technological advancements improving the accuracy and efficiency of bioimpedance analyzers.
The segmental body measurement segment secured USD 397.8 million in 2023, attributed to its pivotal role in providing precise assessments of body composition, including fat mass, lean body mass, and hydration levels.
North America industry will register 474.5 million by 2032, driven by heightened consciousness surrounding health and wellness endeavors, substantial expansion within the wellness and fitness sector, and the implementation of policies advocating for preventive healthcare and wellness initiatives.
Major companies operating in the bioimpedance analyzer industry are Akern, Biodynamics Corporation, Biotekna, Bodystat Ltd., Charder Electronic Co. Ltd., Evolt 360, Fook Tin Technologies Ltd., Inbody Co. Ltd., Maltron International, Omron Corporation, RJL Systems, Inc., SECA GmbH & Co. KG, Selvas Healthcare, Tanita Corporation, Xiaomi among others